![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
X
20
Calao S.r.l. Milano It, based in U.S.A, is a pharmaceutical company.
One of their significant offerings is Gliclazide, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R0-CEP 2001-428 - Rev 01
This Chemical Type CEP, issued on September 19, 2007, remains in force until May 29, 2009, ensuring its reliability within the pharmaceutical industry.
Substance Number 1524 associated with this CEP further emphasizes